12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ErepoXen: Phase I/IIa started

Xenetic said its partner the Serum Institute began an open-label, Indian Phase I/IIa trial to evaluate IV ErepoXen in 40 chronic renal failure patients on dialysis....

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >